Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the †5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with †Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD-a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE)-is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.
Application of the †5-2-1' screening criteria in advanced Parkinson's disease: Interim analysis of DUOGLOBE
Antonini A.;
2020
Abstract
Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the †5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with †Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD-a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE)-is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
